Carbidopa/Levodopa: Vitamin B6 Deficiency, Refractory Seizures and Pharmacovigilance

Carbidopa/levodopa is a foundational treatment for the motor symptoms of Parkinson’s disease. Its safety history illustrates why mature, widely used medicines still need active pharmacovigilance: a biologically plausible metabolic effect can remain clinically inconspicuous for years, then become visible through rare, severe post-marketing cases and lead to a class-wide label change.

On 20 March 2026, the US Food and Drug Administration (FDA) announced that it had notified application holders for carbidopa/levodopa products of a required warning about vitamin B6 deficiency and deficiency-associated seizures. FDA’s review identified 14 cases: 13 reports submitted to FDA and one case in the medical literature. All involved daily levodopa doses above 1,000 mg; some seizures progressed to status epilepticus, two patients died, and all nine patients reported to have received vitamin B6 supplementation had seizure resolution. FDA considered the evidence reasonably supportive of a causal association, while noting that spontaneous reports and literature cases cannot quantify incidence.[1]

The central safety lesson is not that every patient will develop B6 deficiency or seizures. It is that an uncommon, potentially serious event may warrant a label change when the clinical pattern, biochemical rationale, treatment response and seriousness converge. For safety teams, the work is to preserve dose and formulation details, identify deficiency evidence and co-factors, follow outcomes, and avoid turning a small case series into a population-risk estimate.

Scope and Product Identity

This article focuses on carbidopa/levodopa medicines and the FDA’s 2026 US labeling action. The combination is marketed in immediate-release and modified-release oral products, in an enteral suspension, with entacapone, and in formulations that deliver prodrug forms converted in the body to carbidopa and levodopa. Product identity matters: formulations differ in route, delivery, dosing and approval history, although the active treatment pathway is related.[1,2]

The FDA communication applies to products containing carbidopa/levodopa, including named combinations and foscarbidopa/foslevodopa. It does not say that a seizure occurs with every formulation, nor that all products have identical evidence. FDA reported no B6-deficiency-associated seizure cases in its review for carbidopa/levodopa/entacapone products or the injectable product, but concluded that biological plausibility supported a similar potential risk across the product group. The absence of identified cases in those subgroups is not evidence that the risk is impossible.[1]

The regulatory recommendations described here are US-specific. FDA advises healthcare professionals to assess vitamin B6 before starting treatment, periodically during treatment, and when deficiency symptoms arise, and to consider supplementation as needed. This article does not substitute for current local product information or individual clinical judgement. A US communication should trigger a jurisdiction-specific review of the applicable reference safety information rather than automatic global label changes.

From Plant-Derived Molecule to Parkinson’s Therapy

Levodopa’s story began before the modern understanding of Parkinson’s disease. L-DOPA is a naturally occurring amino-acid precursor to dopamine and was isolated from plant material in the early twentieth century. Its therapeutic importance emerged later, through work linking dopamine depletion in the nigrostriatal system with parkinsonian symptoms and experiments showing that levodopa could be converted to dopamine in the brain. Early clinical use was limited by inconsistent response, the high doses required, and peripheral adverse effects.[3,4]

George Cotzias and colleagues helped establish the clinical potential of gradually escalating oral levodopa. Their 1967 report described improvement in parkinsonism with aromatic amino acids, and subsequent work documented sustained treatment effects.[3,5] Levodopa can cross the blood–brain barrier and is converted to dopamine in the central nervous system. Dopamine itself does not readily cross that barrier. However, much of an oral levodopa dose is also decarboxylated in peripheral tissues before it reaches the brain, contributing to nausea, vomiting, cardiovascular effects and the need for high doses.[2,6]

The next development step was to inhibit peripheral aromatic L-amino-acid decarboxylase without blocking the conversion of levodopa to dopamine in the brain. Carbidopa, which does not meaningfully cross the blood–brain barrier, reduces peripheral levodopa conversion. Co-administration therefore increases the fraction of levodopa available to the central nervous system and generally permits a lower levodopa dose with reduced peripheral dopaminergic effects. The combination also changes the vitamin B6 safety question: the 2026 FDA communication describes levodopa metabolism as contributing to B6 depletion and carbidopa binding to the active form of vitamin B6 as an additional route to functional loss.[1,2,10,12]

Merck Sharp & Dohme developed the first product combining levodopa and carbidopa, marketed as Sinemet. FDA records the original US approval under NDA 017555 in 1975. That fixed-dose combination translated biochemical insight into a more practical treatment and became the platform for later strengths and release systems. The product’s origin belongs to the broader Parkinson’s research programme of the mid-twentieth century; it should not be attributed to a single inventor or company as the discovery of levodopa itself.[2,7]

Clinical and Formulation Evolution

The original oral combination was followed by modified-release tablets intended to alter levodopa delivery and support patients with motor fluctuations. Other development paths addressed administration and exposure: carbidopa/levodopa/entacapone combines peripheral decarboxylase inhibition with catechol-O-methyltransferase inhibition; enteral suspension delivers therapy through a pump into the small intestine; and newer products use foscarbidopa/foslevodopa, prodrugs converted to active carbidopa and levodopa, for continuous subcutaneous infusion. FDA approved the foscarbidopa/foslevodopa product in October 2024 for motor fluctuations in adults with advanced Parkinson’s disease.[1,8,9]

These are not interchangeable exposures for case assessment. An immediate-release tablet taken several times daily, a controlled-release tablet, a jejunal infusion and a continuous subcutaneous infusion differ in peak–trough pattern, total daily levodopa, administration complexity and device-related context. FDA’s 2026 review found deficiency-associated seizures in cases involving oral formulations and enteral suspension; it also noted no such cases in the reviewed material for the combination containing entacapone or the injectable product. The communication nevertheless extended the warning rationale across products that contain or deliver the same active treatment pathway.[1]

This history also shows the business pattern of a mature combination therapy. The original branded product emerged from Merck’s development programme; subsequent formulations were developed by multiple sponsors, and generic products expanded the market. Modern prodrug delivery added another innovation layer without replacing the underlying pharmacology. Current case intake should therefore identify the actual medicine, active ingredients or prodrug, dosage form, route, delivery device when relevant, manufacturer or application holder, strength and total daily levodopa exposure rather than recording only “Parkinson’s medication.”[1,2,8,9]

Vitamin B6 and the Safety Rationale

Vitamin B6 refers to a family of vitamers; pyridoxal 5′-phosphate is its active form. FDA identifies two relevant pharmacological observations: B6 levels may fall during levodopa conversion to dopamine, and carbidopa binds the active form of B6, adding to functional loss.[1] The interaction with supplements also needs careful framing. The Sinemet label states that pyridoxine can increase peripheral levodopa decarboxylation and reduce levodopa’s effect when given alone, while carbidopa inhibits this action; it therefore permits Sinemet with supplemental pyridoxine.[2] This established interaction does not negate the newer deficiency warning or justify unsupervised supplementation. Follow the applicable product label and clinical advice.

The safety phenotype is broader than seizures. FDA lists deficiency-associated symptoms such as depression, confusion, inflammation of the lips, tongue or skin, and neuropathic symptoms including numbness, tingling, sharp pain or muscle weakness. These findings are not specific to B6 deficiency and may have other causes, particularly in people with chronic neurological disease. A safety report should therefore record the clinical finding and the evidence supporting the deficiency assessment separately; a seizure alone does not establish a biochemical diagnosis.[1]

The FDA communication also cautions that select antiseizure medicines may further worsen vitamin B6 deficiency. This creates a clinically important possibility: treating the seizure without recognising a deficiency may fail to address a contributing metabolic factor. The article does not prescribe an antiseizure or supplementation regimen. FDA’s advice is to evaluate B6 status and consider supplementation as necessary in consultation with a healthcare professional; individual treatment belongs to the treating clinician.[1]

FDA’s March 2026 Safety Review

On 20 March 2026, FDA announced that it had notified application holders for all drug products containing carbidopa/levodopa that revised prescribing information was required to warn about vitamin B6 deficiency and associated seizures. The communication recommends evaluating vitamin B6 levels before treatment, periodically during therapy, and when symptoms of deficiency appear. It says higher doses may increase risk and that supplementation should be considered when necessary.[1]

FDA identified 14 seizure cases linked to B6 deficiency in people using carbidopa/levodopa: 13 postmarketing reports submitted to FDA and one published case.[1,11] All reviewed cases involved more than 1,000 mg of levodopa per day. Doses above 1,500 mg were associated with a shorter interval from treatment initiation to identification of B6 deficiency. Reported latency ranged from 23 to 132 months. Cases involved oral formulations and enteral suspension, and the seizures were typically focal onset with secondary generalisation; some progressed to status epilepticus.[1]

The case evidence had several converging features. FDA reported elevated homocysteine in four cases, microcytic or normocytic anaemia in three, and neuropsychiatric symptoms in four. These findings may support a deficiency assessment but are not interchangeable with a measured B6 level and may overlap. Two patients died; both had documented low B6 and poorly controlled seizures. Nine patients received B6 supplementation, and seizures resolved in all nine, although most had not responded to multiple antiseizure medicines before supplementation.[1]

FDA found no B6-associated seizure cases in the reviewed material for carbidopa/levodopa/entacapone products or the injectable product. It nevertheless considered a similar risk biologically plausible across products containing or delivering carbidopa/levodopa, noting B6 deficiency observed in trials supporting the injectable product’s original approval. The communication states that FDA concluded there was reasonable evidence of a causal association between carbidopa/levodopa products and B6-deficiency-associated seizures. That regulatory conclusion is stronger than a bare temporal association, but it does not make every individual seizure in a treated patient drug-caused.[1]

The case counts came from postmarketing reports and literature, not from a cohort with known exposure denominators. Underreporting, duplicate or follow-up reports, incomplete testing, changing formulation use, reporting stimulation and confounding can affect the observed set. A count of cases divided by prescriptions or units sold would not be incidence unless the numerator and exposure denominator matched the population, time window, product mix and clinical definition. The appropriate statement is that FDA identified a serious safety signal and required updated warnings—not that 14 cases reveal the rate of harm.[1]

How the Warning Fits the Product Lifecycle

The 2026 warning does not represent the discovery of a new active ingredient, a new indication or the withdrawal of an older formulation. It is a safety update to a long-established treatment family. The earlier development programme established therapeutic benefit for Parkinson’s symptoms; it did not have the scale or follow-up needed to characterise a very rare outcome emerging after years of higher-dose use. Formulation changes also expanded the range of routes and delivery systems over time, creating the need to consider shared pharmacology while retaining product-specific evidence.[1,2,7–9]

The distinction between class-level action and case-level assessment is central. A class-wide warning may be appropriate when mechanism, clinical pattern and seriousness support action across related products. Yet an individual case still requires assessment of the actual product, route, exposure, timing, laboratory findings, other causes, management and outcome. Neither product class membership nor a label warning replaces that work.

Practical Case Assessment

A suspected case should be processed as a clinical event with a potentially relevant exposure and deficiency pathway, not as a diagnosis inferred from the new warning. If a report includes a seizure, capture the seizure and its features; if a low B6 result, anaemia, neuropathy or neuropsychiatric symptom is also described, record each as reported and assess their relationship. Do not convert “possible B6 deficiency” into a confirmed diagnosis without supporting clinical information.

Establishing exposure

Confirm the exact product and active ingredients. Record brand or generic name, manufacturer or application holder when available, dosage form, route, strength, delivery device, lot if relevant, and whether the product contains entacapone or prodrug forms. For a pump-delivered product, document device or infusion interruptions and the reported prescribed versus delivered regimen where known. These details allow comparison with the evidence reviewed by FDA and help distinguish pharmacological risk from administration or product-quality issues.[1,2,8,9]

Reconstruct total daily levodopa exposure rather than recording only the number of tablets or doses. Capture the prescribed and reported dose, dosing schedule, duration, recent escalation or formulation switch, missed or interrupted doses, and use of additional levodopa-containing products. FDA’s reviewed seizure cases involved doses above 1,000 mg/day, with shorter time to identified deficiency among cases above 1,500 mg/day; these observations can guide follow-up but should not be treated as validated clinical cut-offs.[1]

Characterising the event and deficiency evidence

For seizures, seek onset date, focal or generalised presentation, duration, recurrence, progression to status epilepticus, emergency or inpatient treatment, EEG or imaging findings, and outcome. Record whether usual antiseizure medicines were used and whether the reporter described a response. Do not delay urgent clinical care to complete pharmacovigilance follow-up.

For possible B6 deficiency, obtain the actual test, result, unit, laboratory reference range, sampling date, and relationship to supplementation or acute treatment. Ask whether PLP or another B6 measure was tested and whether the result was repeated. Capture supporting features such as homocysteine, haemoglobin and red-cell indices, mucocutaneous symptoms, neuropathy or neuropsychiatric changes, while preserving which findings were observed and which were patient-reported. A normal result obtained after supplementation or outside the event period may not describe the status at seizure onset; retain the chronology and uncertainty.

Follow the course after treatment, including B6 supplementation if administered, antiseizure therapy, changes to the Parkinson’s regimen, recurrence, sequelae and death. In addition to event resolution, document whether any levodopa dose was changed and whether this affected motor symptoms. A positive dechallenge or response to supplementation may inform causality, but it does not alone eliminate alternative explanations or prove a mechanism.

Assessing context and alternative explanations

Review relevant medical history, nutritional status when reported, comorbidities, concurrent medicines and supplements, and other plausible seizure causes. The aim is not to demand an exhaustive neurologic differential from every reporter. It is to identify information that could materially change medical assessment. In a medically complex patient, low B6 may predate treatment or have multiple contributors; seizures may also arise from unrelated neurological, metabolic, infectious or structural causes.

Keep exposure factors separate from events: high daily levodopa dose is an exposure characteristic; vitamin B6 deficiency and seizure are clinical findings. Record both. If a reporter alleges a dosing error, device malfunction, product mix-up or use of an unapproved product, retain those circumstances and route them through the relevant quality, medication-error or device-vigilance pathway as well as pharmacovigilance where required.

The required regulatory case reporting, seriousness assessment, expectedness/listedness and timelines depend on jurisdiction and the information received. Apply the local rules and reference safety information in force for the product and territory. FDA’s class-wide communication is important evidence for US safety review; it does not automatically define reporting requirements or local label status in every country.

Signal Evaluation and Safety Governance

Signal work should translate the FDA communication into a testable, documented surveillance question: are local cases consistent with a B6-deficiency-associated seizure phenotype, and is there evidence that changes the benefit–risk assessment or requires action? The review should begin with a defined data cut, products and territories, case definition, search strategy, coding approach and source inventory. Include spontaneous reports, published literature, medical information, clinical-trial follow-up and product-quality or device channels when they can yield relevant cases.

Deduplicate submissions and reconcile follow-up versions before counting patients. Stratify cases by product and formulation, route, daily levodopa dose, treatment duration, time to onset, measured B6 status, seizure phenotype, concomitant antiseizure medicines, treatment response and outcome. Record when key fields are unavailable. Do not silently exclude cases that lack laboratory confirmation: retain them in an appropriately defined sensitivity or supporting-case set, while distinguishing confirmed deficiency from suspected deficiency.

Quantitative analysis should respect its denominator. If an organisation has reliable patient exposure, dose and time-on-treatment data, it may support a more informative analysis than sales volume alone. Explain coverage, missingness, product attribution and assumptions. Spontaneous-report disproportionality or crude reporting rates can support signal generation but cannot establish incidence or causation. Given FDA’s small case set and no exposure denominator, a local absence of reports is also weak evidence against risk.

A safety review should integrate case narratives, biological plausibility, relevant literature, label history, treatment-response information, competing causes and exposure opportunity. A medical reviewer should document whether each case meets the working definition and how uncertainty was handled. Compare the evidence with the applicable local label and track the FDA labeling action separately from actions in other territories. The assessment should reach an explicit decision—validated, not validated, or requiring further review—with a rationale, owner and reassessment date. For the general process, see the QPPV.com guides to signal detection, signal validation, and listedness, expectedness and reference safety information.

Illustrative Case Review

The following is a constructed teaching scenario, not an FDA case. A person with advanced Parkinson’s disease has taken several carbidopa/levodopa formulations over time. After a dose escalation, the patient develops focal seizures that later generalise. The treating team documents a low vitamin B6 result. Seizures continue despite several antiseizure medicines and resolve after vitamin B6 is given. The initial report does not include the total daily levodopa dose, the date of the blood sample relative to supplementation, or whether any pump-delivered doses were interrupted.

The first pharmacovigilance step is to preserve the report as received and seek the missing timeline. Establish each product, route and dose, reconstruct total daily levodopa, and determine when the dose increased and when the seizures and low B6 result occurred. Capture the actual laboratory result and its context. Ask which antiseizure medicines were given and when B6 was administered, without treating the sequence alone as proof of cause. Seek outcome, recurrence, changes to Parkinson’s therapy, and any relevant co-medications or alternative seizure causes.

The case may be consistent with the phenotype FDA described, especially if the dose, deficiency test and response align. It still requires individual causality assessment: advanced Parkinson’s disease, other illnesses, nutritional factors and other medicines may contribute. The narrative should distinguish the reporter’s observations, objective tests, treatment course and assessor’s interpretation. If a device, administration or product-quality issue is suspected, route that concern through the relevant quality or device process and maintain reconciliation with the safety case.

Common Analytical and Process Failures

• Treating the 14 FDA-identified cases as an incidence estimate or as a complete case universe.
• Coding seizures as “vitamin B6 deficiency” without evidence that deficiency was assessed or established.
• Recording only “carbidopa/levodopa” without formulation, route, total daily levodopa dose and duration.
• Treating 1,000 mg/day as a proven safety threshold or assuming lower doses cannot be associated with deficiency.
• Ignoring the timing of laboratory testing, supplementation, dose changes and seizure onset.
• Counting follow-up versions as separate patients or combining distinct formulations without retaining product identity.
• Assuming seizure resolution after B6 proves causation or that failed antiseizure treatment is unique to this mechanism.
• Treating the FDA communication as a global label change without reviewing local product information.
• Recommending unsupervised supplementation or changing Parkinson’s therapy from a pharmacovigilance article.
• Closing the signal assessment without documenting the data cut, case definition, limitations, rationale and next review point.

QPPV and Safety-System Checklist

These are recommended system controls for a marketing authorisation holder or safety organisation. They are not presented as additional FDA legal requirements.

• Update intake prompts and coding guidance to capture B6 deficiency, seizures, status epilepticus, neuropathy and related clinical features.
• Capture the full product, formulation, route, device, daily levodopa dose, treatment duration and recent dose changes.
• Request laboratory results with units, reference ranges and sampling dates; preserve the chronology relative to supplementation.
• Seek seizure phenotype, management, response to antiseizure treatment and outcome, including response after B6 administration when reported.
• Route serious or refractory seizures promptly for medical review and assess applicable expedited reporting requirements.
• Reconcile spontaneous cases, literature, medical information, patient-support channels, clinical-trial sources, vendors and device/quality systems where relevant.
• Review the FDA warning against current local product information and document separate territory decisions.
• Stratify signal evidence by formulation, dose, duration, deficiency evidence and outcome; explicitly describe missing data and denominator limits.
• Record the safety question, data cut, search strategy, deduplication, medical assessment, decision rationale, escalation and reassessment owner.
• Revisit training and case follow-up prompts after material label or regulatory changes.

Key Takeaways

• Levodopa’s clinical value emerged from mid-twentieth-century research; adding the peripheral decarboxylase inhibitor carbidopa improved delivery and tolerability and led to the first fixed combination approved by FDA in 1975.
• The treatment family now includes several formulations and delivery systems. Product, route and exposure details remain essential in safety case assessment.
• FDA’s March 2026 communication required warning revisions for carbidopa/levodopa products after identifying 14 B6-deficiency-associated seizure cases; every reviewed case involved more than 1,000 mg/day levodopa, but that observation is not a validated threshold or incidence estimate.
• Refractory seizures, deficiency evidence and reported response to B6 formed a clinically important pattern. Two fatalities were reported; all nine patients with reported B6 supplementation had seizure resolution.
• The warning is a class-level regulatory action, while causality and reporting assessments remain case- and jurisdiction-specific.
• Strong pharmacovigilance preserves clinical chronology, actual test results, dose and formulation, alternative explanations, product identity, uncertainty and the rationale for each signal decision.

References

1. U.S. Food and Drug Administration. FDA Is Requiring Warning about Vitamin B6 Deficiency and Associated Seizures for Drug Products Containing Carbidopa/Levodopa. Drug Safety Communication, 20 March 2026. FDA communication
2. U.S. Food and Drug Administration. Sinemet (carbidopa and levodopa) tablets: Prescribing Information, revised 2026. FDA label PDF
3. U.S. Food and Drug Administration. NDA 214869, Chemistry Review. 2022. Notes that Merck Sharp & Dohme developed the first carbidopa/levodopa product, Sinemet, approved in 1975. FDA review
4. Fahn S. The history of dopamine and levodopa in the treatment of Parkinson’s disease. Movement Disorders. 2008;23 Suppl 3:S497–S508. PubMed
5. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. New England Journal of Medicine. 1967;276:374–379. PubMed
6. Cotzias GC, Papavasiliou PS, Gellene R. Modification of Parkinsonism—chronic treatment with L-dopa. New England Journal of Medicine. 1969;280:337–345. PubMed
7. Merck Sharp & Dohme Research Laboratories. Carbidopa and levodopa tablets (Sinemet), NDA 017555. FDA approval history and current prescribing information. Drugs@FDA application record
8. U.S. Food and Drug Administration. Vyalev (foscarbidopa and foslevodopa) injection: Prescribing Information, 2026. FDA label PDF
9. U.S. Food and Drug Administration. Duopa and Stalevo: current prescribing information. Labels include the 2026 vitamin B6 deficiency and seizure warning language. Duopa label PDF; Stalevo label PDF
10. Barbeau A, Mars H, Botez MI, Joubert M. Levodopa combined with peripheral decarboxylase inhibition in Parkinson’s disease. Canadian Medical Association Journal. 1972;106:1169–1174. PubMed
11. Sutter R, Rüegg S, Tschudin-Sutter S. Refractory seizures secondary to vitamin B6 deficiency in Parkinson disease: the role of carbidopa-levodopa. Neurology: Clinical Practice. 2022. PubMed
12. Calne DB, Williams AC, Neophytides A, Plotkin C, Nutt JG. Idiopathic parkinsonism treated with an extracerebral decarboxylase inhibitor in combination with levodopa. British Medical Journal. 1971;3:729–732. PubMed

Regulatory Note

This article is educational and describes US FDA information available through 3 October 2026. The FDA communication and labels cited here should be checked against current local authorisations and product information before use in another jurisdiction. Clinical assessment, testing, supplementation and treatment decisions belong to qualified healthcare professionals considering the individual patient.